Real-World Utilization of Adalimumab Biosimilar (ABP 501) in Patients with Psoriasis in Europe

被引：0
|
作者：
Jin, Ran [1 ]
Wrest, Eleanor [2 ]
Haughton, James [2 ]
Piercy, James [2 ]
Meadows, Rachel [2 ]
Radziszewski, Waldemar [1 ]
机构：
[1] Amgen Inc, Thousand Oaks, CA USA
[2] Adelphi Real World, Bollington, England
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：AB216 / AB216
页数：1
相关论文
共 50 条
  • [21] Effectiveness and safety of switching to adalimumab biosimilar ABP 501 in Crohn's disease
    Viscido, Angelo
    Latella, Giovanni
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2021, 113 (02) : 154 - 155
  • [22] USE OF ADALIMUMAB BIOSIMILAR ABP 501 IN CROHN'S DISEASE: AN OBSERVATIONAL STUDY
    Ribaldone, D. G.
    Vernero, M.
    Pellicano, R.
    Morino, M.
    Saracco, G. M.
    Astegiano, M.
    DIGESTIVE AND LIVER DISEASE, 2020, 52 : S118 - S118
  • [23] A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501
    Markus, Richard
    McBride, Helen J.
    Ramchandani, Monica
    Chow, Vincent
    Liu, Jennifer
    Mytych, Dan
    Fanjiang, Gary
    ADVANCES IN THERAPY, 2019, 36 (08) : 1833 - 1850
  • [24] ADALIMUMAB THERAPEUTIC DRUG MONITORING TEST VALIDATED FOR MEASURING ABP 501 BIOSIMILAR
    Begona Ruiz-Arguello, M.
    Maguregui, Ainara
    Martinez, Antonio
    Nagore, Daniel
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1663 - 1663
  • [25] Adalimumab therapeutic drug monitoring test validated for measuring ABP 501 biosimilar
    Ruiz-Arguello, M. B.
    Maguregui, A.
    Martinez, A.
    Nagore, D.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S265 - S266
  • [26] Demonstration of Functional Similarity Comparing Adalimumab to Biosimilar Candidate ABP 501.
    Born, Teresa
    Velayudhan, Jyoti
    Chen, Yuhfung
    Thomas, Heather
    Pastula, Christina
    Maher, Gwen
    Brown, Ryan
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S661 - S661
  • [27] Effectiveness and safety of adalimumab biosimilar ABP 501 in Crohn's disease: an observational study
    Ribaldone, Davide Giuseppe
    Caviglia, Gian Paolo
    Pellicano, Rinaldo
    Vernero, Marta
    Saracco, Giorgio Maria
    Morino, Mario
    Astegiano, Marco
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2020, 112 (03) : 195 - 200
  • [28] Switching from adalimumab originator to ABP 501 biosimilar: a multicentre North Italian study
    Barberio, B.
    Melatti, P.
    Zingone, F.
    Bertani, L.
    Ferronato, A.
    Gubbiotti, A.
    Massimi, D.
    D'Inca, R.
    Savarino, E. V.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S414 - S414
  • [29] Real-World Dosing and Utilization of Ustekinumab Among Patients With Psoriasis
    Cai, Qian
    Carter, Chureen
    AbuDagga, Azza
    Schenkel, Brad
    Jones, Megan
    Tan, Hiangkiat
    AMERICAN JOURNAL OF PHARMACY BENEFITS, 2014, 6 (03) : 129 - +
  • [30] Treatment Persistence and Switching Patterns of Adalimumab Biosimilar ABP 501 (AMGEVITA®) in Patients with Psoriasis: An Observational Study Using German and French Pharmacy Claims Databases
    Jin, Ran
    Kruppert, Silvia
    Scholz, Florian
    Duret, Stephanie
    Morand, Francois
    Collier, David
    Kricorian, Greg
    Kay, Jonathan
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB242 - AB242
12345